drugset / Trial / NCT04867551

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

NCT04867551

Phase 2 Completed 7 enrolled Kissei Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

Timeline

Start
2021-05-15
Primary completion
2021-09-06
Completion
2021-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject KDT-3594 Unknown Oral

Indications